Why Indian Critical Drug Exports are Surging in 2026: The Role of FTAs

India’s critical drug exports are gaining strong global traction in 2026, as rising demand for generic medicines, oncology therapies, vaccines, and specialty pharmaceuticals coincides with expanding trade partnerships and finalized FTAs with major economies.

---

India has accelerated its economic and trade engagements in 2026, placing the country’s pharmaceutical industry increasingly in the global spotlight. Over the past few years, particularly since 2020-21, India has expanded its capabilities in the production of critical drugs, vaccines, and generic medicines, reinforcing its position as a key pharmaceutical manufacturing hub.

While a large share of production continues to support domestic healthcare requirements, global demand for Indian pharmaceutical products has also risen strongly in 2026, with the United States and several European markets emerging as major export destinations.

ALSO READ: Zero Duties, Big Gains: India-New Zealand FTA Opens New Doors

India’s FY 2025-2026 pharma export statistics

Find Business Support

Stay ahead of India’s evolving trade regulations with expert market intelligence and advisory support.

India’s pharmaceutical and drug formulation exports during April-February 2026 continued to be led by retail medicaments, chronic disease therapies, antibiotics, vaccines, and specialty drugs. As per the Department of Commerce, under the Union Ministry of Commerce and Industry, the latest export profile underscores India’s growing importance as a global supplier of cost-effective generic medicines and finished pharmaceutical formulations.

Among all product categories, “other medicaments put up for retail sale”, HS code 30049099 remained the largest export segment by a substantial margin, with export value reaching nearly US$9.97 billion.

India’s Exports of Top Products under HSN Code 3004 in FY 2025-26* (April to February)
HS code	Product category	Export value (US$ million)
30049099	Other medicaments put up for retail sale	9,976.21
30049049	Other anti-cancer drugs	921.79
30049079	Other antihypertensive drugs	871.72
30049069	Anti-inflammatory, analgesic and antipyretic drugs	829.24
30049039	Gastrointestinal drugs and antacids	610.81
30021500	Immunological products	347.65
30042019	Cephalosporins and derivatives	319.38
30049081	Anti-epileptic medicines	289.47
30049029	Antifungal and antiprotozoal medicines	274.20
30041030	Amoxycillin formulations	249.21

Source: Department of Commerce, Ministry of Commerce and Industry, GoI

*Kindly note that provisional trade data for FY 2025-26 is available between April and February. The complete figures are expected to be released by the DoC in the coming weeks.

The category reflects the scale and competitiveness of India’s finished dosage formulation industry in international markets.

Chronic disease therapies drive global demand

The DoC export data also highlights a strong rise in global demand for therapies related to non-communicable diseases (NCDs), indicating increasing international reliance on India for affordable chronic disease treatment solutions. Countries across North American regions, Europe, Latin America, and Asia are increasingly sourcing affordable chronic disease medication from India as healthcare costs continue to rise globally in 2026.

India’s growing export share in oncology, cardiovascular treatment, respiratory care, and diabetes management reflects the country’s increasing integration into global healthcare procurement systems.

India’s export of vaccines and specialty therapies

DoC’s export data points to the rising contribution of biologics, vaccines, and immunological products within India’s pharmaceutical trade basket. Exports of immunological products reached US$347.65 million during FY 2025-26 (April-February), while vaccine categories covering MMR, polio, rabies, hepatitis, tuberculosis, and veterinary vaccines continued to record notable export volumes.

In addition, India’s pharmaceutical exports are increasingly diversifying into specialty and higher-value therapeutic segments. These include anti-epileptic medicines, anti-malarial formulations, insulin and hormone-based therapies, diagnostic reagents, and immunological and prophylactic preparations, reflecting the sector’s gradual movement toward more advanced and specialized healthcare products.

Expanding global footprint in antibiotics and anti-infective drug exports

India continues to maintain a strong global presence in anti-infectives and generic antibiotics, a segment where the country has historically been among the world’s leading pharmaceutical suppliers. As of 2025, India ranked as the world’s fourth-largest exporter of antibiotics, supported by its large-scale generic manufacturing ecosystem and competitive production costs.

The export basket includes a broad range of anti-microbial formulations catering to both developed and emerging healthcare markets.

Source: Department of Commerce, Ministry of Commerce and Industry, GoI

*Kindly note that provisional trade data for FY 2025-26 is available between April and February. The complete figures are expected to be released by the DoC in the coming weeks.

Rising international demand for low-cost generic antibiotics, combined with supply diversification strategies across major economies, is expected to further strengthen India’s position in the global anti-infective drug market.

Strategic shifts: Transitioning to zero-duty European markets

In 2026, Europe has emerged as one of the most important growth regions for India’s pharmaceutical and drug formulation exports, particularly for retail medicaments and therapeutic products classified under HS Code 300490. The steady rise in exports across major European Union (EU) markets reflects increasing demand for affordable generic medicines, chronic disease therapies, and specialty formulations manufactured in India.

Between 2024 and 2025, France remained the largest EU importer of Indian pharmaceutical products under HS Code 300490, followed closely by the Netherlands, Germany, Belgium, and Malta.

Source: ITC Trade Map

India-EU FTA influence on pharma trade

The growth trend runs in parallel with the India-EU free trade agreement (FTA) negotiations being finalized in January 2026. The FTA is expected to influence the long-term trajectory of India’s pharmaceutical exports by improving market access conditions, streamlining regulatory cooperation, and reducing non-tariff trade barriers for Indian drug manufacturers.

For Indian pharmaceutical exporters, Europe is gradually evolving from a traditional regulated market into a long-term strategic growth destination, particularly as healthcare demand rises across aging European populations and governments seek affordable alternatives for chronic disease treatment.

ALSO READ: India FTA Tracker 2026: Live Updates on Trade & Economic Pacts

Therapeutic focus: Rise of oncology and biologics

It must be noted that the US continues to dominate as India’s largest pharmaceutical export destination, particularly for oncology drugs and retail medicines.

Source: ITC Trade Map

The export expansion across Latin America, ASEAN, the Middle East, and Eastern Europe also indicates that India’s pharmaceutical footprint is becoming increasingly diversified geographically.

Conclusion

Find Business Support

Want to know more about investing in India’s pharmaceutical industry? Contact our experts

From affordable generic medicines and chronic disease therapies to vaccines, biologics, and anti-infective drugs, India is strengthening its position as a reliable supplier of critical healthcare products across major international markets.

The expansion of pharmaceutical exports to the US, Europe, ASEAN, Latin America, and the Middle East also reflects growing global dependence on India’s cost-competitive manufacturing ecosystem and large-scale generic drug capabilities.

At the same time, the finalization of FTAs, particularly the India-EU trade agreement, is expected to further boost the sector by improving market access, reducing trade frictions, and strengthening regulatory cooperation. As global healthcare systems increasingly prioritize affordable medicines and diversified sourcing networks, India’s pharmaceutical industry is likely to remain a key driver of global drug supply and healthcare accessibility.

• Previous Article India Electrical Appliances QCO 2026: BIS Certification Guide for Foreign Manufacturers
• Next Article